Meloxicam/rizatriptan
Overview
Meloxicam/rizatriptan, sold under the brand name Symbravo, is a fixed-dose combination medication used for the treatment of migraine. It is a combination of meloxicam, a nonsteroidal anti-inflammatory medication; and rizatriptan (as rizatriptan benzoate), a serotonin (5-HT) 1B/1D receptor agonist (triptan). It is taken by mouth.[1] WP
Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.[2] WP
Uses, dosage and effects
Medical uses
Meloxicam/rizatriptan is indicated for the acute treatment of migraine with or without aura in adults.[1]
Legal status
Legal status
Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.[2] WP
Chemistry
Harm reduction information
No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.
User reports
Erowid erowid.org
ListingsBluelight bluelight.org
ListingsReddit reddit.com
ListingsPop culture
No references added yet.
Add a reference
Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.
Opens when accounts launch.
Sources
- Journal / agency Symbravo- meloxicam, rizatriptan tablet. 24 February 2025
- Other Axsome Therapeutics Announces FDA Approval of Symbravo (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults. 30 January 2025
- Journal / agency Karsan N, Goadsby PJ. New Oral Drugs for Migraine. CNS Drugs. September 2022. doi:10.1007/s40263-022-00948-8 · PMID 36031682 · PMC9477894
Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.